2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Moderna company profile · mRNA medicines · Spikevax · history · financial snapshot · S&P 500 rank #145 · 莫德納公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | MRNA (NASDAQ) |
| Company | Moderna, Inc. |
| GICS sector / industry | Health Care (XLV) / Biotechnology |
| S&P 500 rank (by weight) | #145 · 0.13% (Oct 31, 2026) |
| Sector rank | #22 in Health Care (Oct 31, 2026) |
| Headquarters | 325 Binney Street, Cambridge, Massachusetts (principal executive offices) |
| Founded | 2010 (as ModeRNA Therapeutics, Inc.) |
| CEO | Stéphane Bancel (Chief Executive Officer) |
| Employees | Approximately 4,700 full-time (Dec 31, 2025, in 18 countries) |
| Market cap | $88.52B (Oct 31, 2026) |
| SEC filings | EDGAR — CIK 0001682852 |
WHAT IT DOES
Moderna is a biotechnology company built on messenger RNA (mRNA): synthetic mRNA instructions that teach a patient’s own cells to make a protein — a viral antigen for a vaccine, or a therapeutic protein — and then degrade. The platform’s first proof was Spikevax, the COVID-19 vaccine that went from sequence to emergency authorization in under a year in 2020. FY2025 total revenue was $1.94B, down 40.0% year on year as the COVID franchise faded.
Moderna now has three commercial products: the COVID vaccines Spikevax and mNEXSPIKE (launched commercially in 2025) and mRESVIA, the RSV vaccine for older and at-risk adults approved by the FDA in May 2024. Product sales were $1.82B in FY2025 — COVID-19 products $1.81B and RSV $8M — with the remaining $126M from grants, collaborations, licenses and stand-ready manufacturing arrangements.
The investment question is whether the platform produces a second franchise before the cash runs down. Moderna ended the COVID windfall years with a deep pipeline — 44 treatment and vaccine candidates, 37 in clinical trials by the company’s count — spanning influenza, rare diseases and oncology, including individualized cancer vaccines. FY2025’s net loss narrowed to $2.82B from $3.56B as restructuring cut the cost base.
REVENUE MIX — FY2025 TOTAL REVENUE
| Segment | Revenue | Share | YoY |
|---|---|---|---|
| Product sales — COVID-19 | $1,810M | 93.1% | |
| Product sales — RSV | $8M | 0.4% | |
| Grants, collaborations, licenses, stand-ready | $126M | 6.5% | |
| Total revenue | $1,944M | 100% | −40.0% |
HISTORY
| Year | Milestone |
|---|---|
| 2010 | Founded as ModeRNA Therapeutics, Inc., to commercialize mRNA medicines |
| 2018 | Shares open for trading on NASDAQ on December 7 (ticker MRNA) |
| 2020 | COVID-19 vaccine developed with Operation Warp Speed support; emergency authorization in December |
| 2024 | mRESVIA RSV vaccine approved by the FDA in May |
| 2025 | mNEXSPIKE COVID vaccine launched commercially; total revenue falls 40% as the COVID franchise fades |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Total revenue | $1.94B (−40.0% YoY, vs $3.24B) |
| Product sales | $1.82B (COVID-19 $1.81B, RSV $8M) |
| Operating loss | −$3.07B |
| Net loss | −$2.82B (vs −$3.56B) |
| Loss per share | $7.26 (vs $9.28; basic, diluted equals basic in a loss year) |
| Operating cash flow | $1.87B |
| Employees | Approximately 4,700 full-time (Dec 31, 2025) |
| Fiscal year | Ends Dec 31 (FY2025 ended Dec 31, 2025) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Moderna is the index’s mRNA platform bet: at a 0.13% weight and #22 in Health Care, its results track whether mRNA becomes a general drug modality or remains a COVID-era exception.
Its pipeline read-across matters beyond one company: success in flu, RSV or individualized cancer vaccines would validate the platform for the whole field, while failure would re-rate every mRNA name in the index.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Oct 31, 2026 crawl) · StockAnalysis (market cap — Oct 31, 2026 crawl) |
| Financials | Moderna FY2025 Form 10-K (SEC EDGAR, filed Feb 20, 2026; fiscal year ended Dec 31, 2025) |
| Sector classification | GICS (Biotechnology) via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
| Library note | Chart library not yet published: this draft is a text version; the chart overlay follows on data release. No chart data is invented. |
FINANCIALS
公司快照
| 代碼 | MRNA(NASDAQ) |
| 公司 | Moderna, Inc. |
| GICS 板塊/行業 | 醫療保健(XLV)/生物科技 |
| 標普500排名(按權重) | #145 · 0.13%(2026 年 10 月 31 日) |
| 板塊內排名 | 醫療保健第 #22(2026 年 10 月 31 日) |
| 總部 | 美國麻薩諸塞州劍橋 Binney Street 325 號(主要行政辦公室) |
| 成立 | 2010 年(原名 ModeRNA Therapeutics, Inc.) |
| 行政總裁 | Stéphane Bancel(行政總裁) |
| 員工 | 約 4,700 名全職(2025 年 12 月 31 日,遍佈 18 國) |
| 市值 | $88.52B(2026 年 10 月 31 日) |
| SEC 申報 | EDGAR — CIK 0001682852 |
業務概覽
莫德納是一家以信使核糖核酸(mRNA)為基礎的生物科技公司:合成 mRNA 指令教導患者自身細胞製造一種蛋白質——疫苗的病毒抗原,或治療性蛋白——隨後降解。該平台的首個證明是 Spikevax 新冠疫苗,2020 年從序列到緊急授權不到一年。FY2025 總收入為 $1.94B,同比下降 40.0%,因新冠業務消退。
莫德納現有三款商業產品:新冠疫苗 Spikevax 與 mNEXSPIKE(2025 年商業上市),以及 2024 年 5 月獲 FDA 批准的 RSV 疫苗 mRESVIA。FY2025 產品銷售 $1.82B——新冠產品 $1.81B、RSV $8M——其餘 $126M 來自補助、合作、授權與備便製造安排。
投資問題是平台能否在現金耗盡前產生第二個業務支柱。莫德納在新冠豐收年份結束時擁有深厚的管線——公司統計 44 個治療與疫苗候選藥,其中 37 個已進入臨床試驗——涵蓋流感、罕見病與腫瘤學,包括個體化癌症疫苗。FY2025 淨虧損收窄至 $2.82B(FY2024 為 $3.56B),因重組削減成本基礎。
收入構成 — FY2025 總收入
| 板塊 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| 產品銷售 — 新冠 | $1,810M | 93.1% | |
| 產品銷售 — RSV | $8M | 0.4% | |
| 補助、合作、授權、備便製造 | $126M | 6.5% | |
| 總收入 | $1,944M | 100% | −40.0% |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 2010 | 以 ModeRNA Therapeutics, Inc. 之名成立,致力 mRNA 藥物商業化 |
| 2018 | 12 月 7 日股票在 NASDAQ 開始交易(代碼 MRNA) |
| 2020 | 在 Operation Warp Speed 支持下開發新冠疫苗;12 月獲緊急授權 |
| 2024 | 5 月 mRESVIA RSV 疫苗獲 FDA 批准 |
| 2025 | mNEXSPIKE 新冠疫苗商業上市;新冠業務消退,總收入下降 40% |
競爭地位
財務快照 — FY2025
| 總收入 | $1.94B(同比 −40.0%,FY2024 為 $3.24B) |
| 產品銷售 | $1.82B(新冠 $1.81B、RSV $8M) |
| 營業虧損 | −$3.07B |
| 淨虧損 | −$2.82B(FY2024 為 −$3.56B) |
| 每股虧損 | $7.26(FY2024 為 $9.28;基本每股,虧損年度攤薄等於基本) |
| 經營現金流 | $1.87B |
| 員工 | 約 4,700 名全職(2025 年 12 月 31 日) |
| 財政年度 | 截至 12 月 31 日(FY2025 截至 2025 年 12 月 31 日) |
主要風險
對標普500的重要性
莫德納是指數中的 mRNA 平台賭注:權重 0.13%、醫療保健第 #22,其業績追蹤 mRNA 能否成為通用藥物模式,抑或只是一次新冠時代的例外。
其管線的啟示超出單一公司:流感、RSV 或個體化癌症疫苗若成功,將為整個領域驗證該平台;若失敗,則會重新評級指數中每一家 mRNA 公司。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 31 日抓取)· StockAnalysis(市值——2026 年 10 月 31 日抓取) |
| 財務 | 莫德納 FY2025 Form 10-K(SEC EDGAR,2026 年 2 月 20 日申報;財政年度截至 2025 年 12 月 31 日) |
| 板塊分類 | GICS(生物科技),據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
| 圖庫說明 | 圖表庫尚未發佈:本稿為文字版;圖表於數據放行後補上。不發明圖表數據。 |
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-31 04:14 · updated 2026-11-14 23:52 · rev 5